All In Biotech

Drug Trial Radar · NCT01594749

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy

Last checked: Nov 19, 2026Latest source record: Sep 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,015 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,015

Actual

Start

Sep 24, 2012

Primary completion

Nov 3, 2014

Study completion Nov 3, 2014

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 antagonist and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

Conditions

  • Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

  • Fosaprepitant dimeglumineDrug

  • Fosaprepitant PlaceboDrug

  • DexamethasoneDrug

  • OndansetronDrug

  • Dexamethasone PlaceboDrug

  • Ondansetron PlaceboDrug

  • Rescue TherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC)Time frame: 25 to 120 hours after initiation of MEC
  2. Percentage of Participants With Infusion-site ThrombophlebitisTime frame: Day 1 through Day 17, inclusive
  3. Percentage of Participants With Severe Infusion-site ReactionsTime frame: Day 1 through Day 17, inclusive

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.